Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure

• Status: Completed
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universiti Kebangsaan Malaysia Medical Centre
• Treatments: Dydrogesterone; Letrozole

Criteria

Inclusion Criteria:

• Women of 18 to 40 years of age

• No significant pre-existing major medical.

• Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained).

• Regular menstrual cycle atleast 3 months prior to treatment

• Not taking any hormonal treatment for atlest 3months prior to recruitment

• Agreed to participate

Exclusion Criteria:

• Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation.

• Poor quality of embryo

• Suboptimal endometrial thickness(<8mm) during the embryo transfer (ET).

• On hormonal therapy prior to recruitment.

• Not agreed to participate